SynthesisJournal of translational medicine2026
Global prevalence and ethnic variation of pathogenic BRCA1/2 variants in breast cancer: a systematic review and meta-analysis.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe breast cancer (BC) susceptibility genes 1 (BRCA1) and BC susceptibility genes 2 (BRCA2) are critical genes associated with hereditary breast cancer, and their mutation prevalence might greatly vary across different ethnic populations. This systematic review and meta-analysis evaluated global ethnic variation in BRCA1/2 mutation prevalence among breast cancer (BC) patients.
methodsWe searched five databases for studies published between 2015 and 2025 that reported BRCA1/2 mutations in BC patients across various ethnic groups. 45 studies met the inclusion criteria, comprising about 44,000 BC patients. Data were stratified into two categories: (1) the frequency of all reported variants (including high-frequency polymorphisms) to assess global reporting patterns, and (2) the estimated clinical prevalence of confirmed Pathogenic and Likely Pathogenic (PLP) variants (excluding benign polymorphisms) for cancer risk assessment in broad ethnic categories (Asian, Chinese, Black/African descent, Hispanic/Latino, Middle Eastern/North African, European, Ashkenazi Jewish, and others).
resultsThe prevalence of BRCA1/2 mutations in BC patients displayed substantial global variability. Heterogeneity was high (I² >95%, p < 0.001), reflecting diverse study populations and designs. The frequency of all reported variants varied substantially, reaching up to 17% in specific subgroups due to the inclusion of common polymorphisms. However, after strict filtering, the clinical prevalence of PLP variants ranged from < 1% to 5% in most ethnic groups, aligning with expected population risk.
conclusionEthnicity significantly influences BRCA1/2 mutation distribution among BC patients globally. These findings underscore the importance of population-tailored genetic testing approaches and the necessity of including underrepresented groups in genetic research to enhance risk assessment and personalized cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.